Drugs / Td-pur
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT02946190 Background | Oct 2016 → Mar 2017 | pertussis | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 3 | NCT04618939 Comparator | Oct 2016 → Apr 2017 | diphtheria, tetanus | Boryung Biopharma Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Td-pur | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04618939 ↗ |
| Modality | Vaccine | “Three vaccines will be used in the study. The BioNet-Asia study vaccine (Pertagen®), Td-pur® (Novartis/GSK) which will be concomitantly administered with the study vaccine, and...” NCT02946190 ↗ |
| Route | Intramuscular | “If applicable, Td-pur® will be administered in the contralateral deltoid.” NCT02946190 ↗ |